RBCL — RBC Life Sciences Income Statement
0.000.00%
Last trade - 00:00
Consumer CyclicalsHighly SpeculativeMicro Cap
2010 December 31st | 2011 December 31st | 2012 December 31st | 2013 December 31st | 2014 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 28.2 | 28.4 | 25.2 | 25.5 | 28.3 |
Cost of Revenue | |||||
Gross Profit | 13.7 | 14.3 | 12.6 | 12 | 15.6 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 27.1 | 28.5 | 25.6 | 26.1 | 28.9 |
Operating Profit | 1.04 | -0.071 | -0.464 | -0.625 | -0.625 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 0.891 | -0.211 | -0.59 | -0.736 | -0.721 |
Provision for Income Taxes | |||||
Net Income After Taxes | 0.558 | -0.071 | -0.361 | -0.5 | -0.603 |
Net Income Before Extraordinary Items | |||||
Net Income | 0.558 | -0.071 | -0.361 | -0.5 | -0.603 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 0.558 | -0.071 | -0.361 | -0.5 | -0.603 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.025 | -0.003 | -0.292 | -0.225 | -0.272 |
Dividends per Share |